Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR

Leukemia. 2009 Feb;23(2):396-9. doi: 10.1038/leu.2008.183. Epub 2008 Jul 10.
No abstract available

Publication types

  • Evaluation Study
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Microfluidic Analytical Techniques / instrumentation
  • Nanotechnology / instrumentation*
  • Point Mutation*
  • Polymerase Chain Reaction / methods*
  • Polymerase Chain Reaction / standards
  • Sensitivity and Specificity

Substances

  • Fusion Proteins, bcr-abl